



DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

**NOTICE OF MEETING TO SOLICIT PUBLIC COMMENTS AND INTENT TO ACT
UPON AMENDMENTS TO THE NEVADA MEDICAID SERVICES MANUALS (MSM)
AND THE NEVADA MEDICAID OPERATIONS MANUAL (MOM)**

AGENDA

Date of Publication: July 25, 2019

Date and Time of Meeting: August 27, 2019 at 9:30 AM or upon completion of the amendments to the State Plan for Medicaid Services public hearing

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: Nevada State Legislative Building
401 S. Carson Street, Room 3137
Carson City, Nevada 89701

Place of Videoconference Grant Sawyer Office Building
555 E. Washington Avenue, Room 4412E
Las Vegas, Nevada 89101

Teleconference: (888) 363-4735

Access Code: 1961395

AGENDA

1. General Public Comments (Because of time considerations, the period for public comment by each speaker or organization may be limited to three minutes and speakers are urged to avoid repetition of comments made by previous speakers.)
2. For possible action: Discussion and adoption of changes to MSM Chapter 300 – Radiology Services

Revisions to MSM Chapter 300 are being proposed to remove the prior authorization requirements for Magnetic Resonance Imaging (MRI), Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS) and Positron Emission Tomography (PET) scans.

Entities Financially Affected: The proposed change affects Medicaid enrolled providers delivering MRI, MRA, MRS and PET scan services. Those provider types (PT) include but are not limited to: Outpatient Hospitals (PT 12), Physician, M.D., Osteopath (PT 20), Advanced Practice Registered Nurse (PT 24), Radiology (PT 27) and Physician Assistant (PT 77).

Financial impact on local government: Unknown at this time.

Effective date: September 1, 2019.

- a. Presentation of MSM Chapter 300
- b. Public comment on proposed changes
- c. Adoption of proposed changes

3. For possible action: Discussion and adoption of changes to MSM Chapter 100 – Medicaid Program

The DHCFP proposes to move MSM Chapter 100, Section 104.3 – Health Insurance Premium Program (HIPP) to a new MOM Chapter 900 – Cost Avoidance Programs. MOM Chapter 900, Section 903 outlines the program, eligibility determination and cost-effectiveness of the program.

Entities Financially Affected: None.

Financial impact on local government: None.

Effective date: August 28, 2019.

- a. Presentation of MSM Chapter 100
- b. Public comment on proposed changes
- c. Adoption of proposed changes

4. For possible action: Discussion and adoption of changes to MOM Chapter 900 – Cost Avoidance Programs

MOM Chapter 900 – Cost Avoidance Programs is being proposed to encompass the following categories: HIPP, incarcerations, Medicare Advantage Plan, Medicare Premium Buy-In and Public Assistance Reporting Information System (PARIS). These changes are being made to improve the organization and placement of contents in the MOM regarding internal DHCFP operations.

Entities Financially Affected: None.

Financial impact on local government: None.

Effective date: August 28, 2019.

- a. Presentation of MOM Chapter 900
- b. Public comment on proposed changes
- c. Adoption of proposed changes

5. For possible action: Discussion and adoption of changes to MSM Chapter 1200 – Prescribed Drugs

The DHCFP proposes revisions to Medicaid Services Manual Chapter 1200, Appendix A, to reflect recommendations approved on April 25, 2019 by the Drug Use Review (DUR) Board. The proposed changes include revisions to the existing policy on Agents Used for the Treatment of Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD), Transdermal Fentanyl, Buprenorphine/Naloxone and Vivitrol® (naltrexone). These proposed changes also include the addition of new prior authorization criteria for Lucemyra™ (lofexidine) and Xyosted™ (testosterone enanthate).

Entities Financially Affected: Providers who prescribe, dispense or administer this drug may be affected by this change, including but not limited to the following PTs: Outpatient Surgery (PT 10); Hospital, Inpatient (PT 11); Hospital, Outpatient (PT 12); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Public (PT 16); Special Clinics (PT 17); Nursing Facility (PT 19); Physician/Osteopath (PT 20); Podiatrist (PT 21); Advanced Practice Registered Nurse (PT 24); Pharmacy (PT 28); Home Health Agency (PT 29); Ambulatory Surgical Centers, Freestanding (PT 46); Indian Health Programs and Tribal Clinics (PT 47); Indian Health Service Hospital, Inpatient (Tribal) (PT 51), Indian Health Service Hospital, Outpatient (Tribal) (PT 52); Transitional Rehabilitative Center, Outpatient (PT 55); Inpatient Rehabilitation and Long Term Acute Care (LTAC) Specialty Hospitals (PT 56); Hospice (PT 64); Hospice, Long Term Care (PT 65); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Private (PT 68); Nurse Anesthetist (PT 72); Critical Access Hospital (CAH), Inpatient (PT 75); Audiologist (PT 76); Physician’s Assistant (PT 77); Indian Health Service Hospital, Inpatient (Non-Tribal) (PT 78); Indian Health Service Hospital, Outpatient (Non-Tribal) (PT 79).

Financial impact on local government: There is no financial impact on local government.

Effective date: September 2, 2019.

- a. Presentation of MSM Chapter 1200
- b. Public comment on proposed changes
- c. Adoption of proposed changes

6. Adjournment

Nevada Medicaid is unaware of any financial impact to other entities or local government due to this public hearing, other than as stated above.

PLEASE NOTE: Items may be taken out of order. Items may be pulled or removed from the agenda at any time. All public comment may be limited to three minutes.

The DHCFP is exempt from Chapter 233B according to NRS 233B.039 and is not required to comply with the open meeting law in this process.

This notice and agenda have been posted at <http://dhcfnv.gov/> and <https://notice.nv.gov/>.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP website <http://dhcfnv.gov/>. The agenda posting of this meeting can be viewed at the following locations: Carson City Central Office, Las Vegas District Office, Reno District Office and Elko District Office and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to Jenifer Graham at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, Nevada 89701.

All persons that have requested in writing to receive the public hearing agendas have been duly notified by mail or e-mail.

We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at: jenifer.graham@dhcfnv.gov, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Jenifer Graham at (775) 684-3685.
